[go: up one dir, main page]

AU2002226028A1 - Mutant human factor ix with an increased resistance to inhibition by heparin - Google Patents

Mutant human factor ix with an increased resistance to inhibition by heparin

Info

Publication number
AU2002226028A1
AU2002226028A1 AU2002226028A AU2602802A AU2002226028A1 AU 2002226028 A1 AU2002226028 A1 AU 2002226028A1 AU 2002226028 A AU2002226028 A AU 2002226028A AU 2602802 A AU2602802 A AU 2602802A AU 2002226028 A1 AU2002226028 A1 AU 2002226028A1
Authority
AU
Australia
Prior art keywords
heparin
inhibition
increased resistance
human factor
mutant human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226028A
Inventor
John P. Sheehan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Board Of Regents Unversity Of Texas Systems
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2002226028A1 publication Critical patent/AU2002226028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2002226028A 2000-11-14 2001-11-13 Mutant human factor ix with an increased resistance to inhibition by heparin Abandoned AU2002226028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24832600P 2000-11-14 2000-11-14
US60/248,326 2000-11-14
PCT/US2001/047276 WO2002040544A2 (en) 2000-11-14 2001-11-13 Mutant human factor ix with an increased resistance to inhibition by heparin

Publications (1)

Publication Number Publication Date
AU2002226028A1 true AU2002226028A1 (en) 2002-05-27

Family

ID=22938622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226028A Abandoned AU2002226028A1 (en) 2000-11-14 2001-11-13 Mutant human factor ix with an increased resistance to inhibition by heparin

Country Status (3)

Country Link
US (1) US7125841B2 (en)
AU (1) AU2002226028A1 (en)
WO (1) WO2002040544A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
CA2463301A1 (en) * 2004-04-22 2005-10-22 Atanas Iliev Lalev Method for detecting protein interactions - affinity purification with switching the ligand
PT2380985E (en) 2003-09-23 2014-03-26 Univ North Carolina Cells expressing vitamin k epoxide reductase and use thereof
ATE489105T1 (en) * 2004-03-19 2010-12-15 Baxter Int FACTOR IXA FOR THE TREATMENT OF BLEEDING DISORDERS
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AU2008209985A1 (en) 2007-02-01 2008-08-07 Baxter Healthcare S.A. Improved fix-mutant proteins for hemophilia B treatment
US8022187B2 (en) 2007-02-01 2011-09-20 Baxter International Inc. FVIII-independent FIX-mutant proteins for hemophilia A treatment
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
ES2687038T3 (en) 2008-09-15 2018-10-23 Uniqure Biopharma B.V. Factor IX polypeptide mutant, its uses and a method for its production
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
MY192639A (en) 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
TWI557135B (en) 2010-11-03 2016-11-11 介控生化科技公司 Modified ninth factor multi-peptide and use thereof
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ACTIVE PROTEINS DEPENDENT ON VITAMIN K
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
ES2771208T3 (en) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Factor VIII compositions and methods of preparation and use thereof
HK1212882A1 (en) 2012-07-25 2016-06-24 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
TWI750197B (en) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Methods of using fix polypeptides
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
EP3083933B1 (en) 2013-12-20 2026-01-21 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EA038573B1 (en) 2014-03-24 2021-09-16 Биовератив Терапьютикс Инк. Lyophilized factor ix formulation for preventing bleeding episodes
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (en) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 Factor ix fusion proteins and methods of making and using same
LT3411478T (en) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimized factor viii genes
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
IL322212A (en) 2017-08-09 2025-09-01 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
AU2018338608B2 (en) 2017-09-27 2025-09-11 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
MA52630B1 (en) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. METHODS OF TREATMENT OF HEMOPHILIA A
CN113227385B (en) 2018-08-09 2024-12-24 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use in non-viral gene therapy
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
BR112021020668A2 (en) 2019-04-17 2022-01-11 Codiak Biosciences Inc Exosomes and aav compositions
TW202126284A (en) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2025534659A (en) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド Engineered cells and implantable elements for disease treatment
CN120659872A (en) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 Engineered cells and implantable elements for treating diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000560A1 (en) 1982-08-04 1984-02-16 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
US5614500A (en) * 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
EP0195592B1 (en) 1985-03-15 1992-04-22 Btg International Limited Factor ix protein
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2638643B1 (en) 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
FR2650838A1 (en) * 1989-08-09 1991-02-15 Transgene Sa FACTOR IX EXPRESSION VECTORS IN A SUPERIOR EUKARYOTE CELL, PROCESS FOR THE PREPARATION OF FACTOR IX BY TRANSGENIC ANIMALS, AND FACTOR IX OBTAINED
DE69231401T2 (en) * 1991-03-01 2001-02-08 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville PRODUCTION OF FACTOR-IX
DE69434689D1 (en) * 1993-06-10 2006-05-18 Genetic Therapy Inc ADENOVIRAL VECTORS FOR THE TREATMENT OF HEMOPHILIA
US5521010A (en) * 1994-03-25 1996-05-28 The Furukawa Electric Co., Ltd. Polyethylene for an insulation layer of a power cable and a crosslinked polyethylene insulated power cable using the same
DE4435520A1 (en) * 1994-10-04 1996-04-11 Immuno Ag Process for the separation of recombinant pro-factor IX from recombinant factor IX
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
DE69841982D1 (en) * 1997-03-14 2010-12-16 Philadelphia Children Hospital COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin

Also Published As

Publication number Publication date
WO2002040544A2 (en) 2002-05-23
WO2002040544A9 (en) 2003-05-01
WO2002040544A3 (en) 2002-10-31
US20040110675A1 (en) 2004-06-10
US7125841B2 (en) 2006-10-24

Similar Documents

Publication Publication Date Title
AU2002226028A1 (en) Mutant human factor ix with an increased resistance to inhibition by heparin
AU2001235275A1 (en) Adjustable chair
AU2920801A (en) Transfigurable furniture unit
AU7489900A (en) Music searching methods based on human perception
AU2003256591A1 (en) Variable resistance sensor with common reference leg
AU2001296981A1 (en) Chair control
AU2002234025A1 (en) Elastic laminate
AU2003296178A1 (en) Deodorant with excellent water resistance
AU2001285185A1 (en) Bearing with adjustable setting
AU2001265662A1 (en) Ergometer
AUPQ597500A0 (en) Improved theatre chair
AU2003263692A1 (en) Adjustable chair arrangement
AU2001239241A1 (en) New 3-arylbenzofuranones with electron-withdrawing substituents as stabilizers
AU2002246864A1 (en) Pim kinase-related methods
TW433413U (en) Hob screw structure
AU2001242559A1 (en) Putters
AU2003205963A1 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
AU2001242742A1 (en) Copper-tolerant yeast and pectinase produced by the copper-tolerant yeast
AU2002248178A1 (en) Mutant cells with enhanced resistance to desiccation
AU2002231574A1 (en) Plants with improved resistance
AU2002224783A1 (en) Office chair
AU2002215030A1 (en) Chair
AU2002335232A1 (en) Long chair having massage function
AU2003214130A1 (en) Children's chair
AU2000226557A1 (en) Gliding run segment